Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 10, 2020
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 31, 2019
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 14, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: October 25, 2018
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.
Journal: Cancer chemotherapy and pharmacology
Published: January 09, 2018
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.
Journal: Lung Cancer (Auckland, N.Z.)
Published: November 16, 2017
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 08, 2017
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Journal: Investigational new drugs
Published: December 19, 2016
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 10, 2016
A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers.
Journal: Cancer investigation
Published: April 30, 2016
Last Updated: 09/26/2026